For instance, upregulation of GSDMD in lung cancer or GSDMC in colorectal cancer correlates with poor prognosis and therapeutic resistance, whereas reactivation of GSDME in breast cancer or AIM2 in gastric cancer has been shown to re-sensitize tumors to chemotherapy and inhibit proliferation. This evidence concerns the gene GSDMC and breast carcinoma.